Gallium-67 as a tumor-seeking agent in lymphomas - A review

被引:14
作者
Draisma, A
Maffioli, L
Gasparini, M
Savelli, G
Pauwels, E
Bombardieri, E
机构
[1] Natl Canc Inst, Div Nucl Med, I-20133 Milan, Italy
[2] Univ Leiden Hosp, Dept Diagnost Radiol & Nucl Med, NL-2300 RC Leiden, Netherlands
[3] Osped Maggiore, IRCCS, Div Nucl Med, I-20122 Milan, Italy
关键词
gallium scintigraphy; lymphoma; nuclear medicine techniques;
D O I
10.1177/030089169808400402
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: At present Ga-67 can be considered one of the most widely used viability radiotracers. There is general consensus in the literature that Ga-67 has the highest clinical value in the management of lymphoma patients. Methods: We critically discuss the role of gallium scintigraphy in lymphoma patients on the basis of the experience of the Nuclear Medicine Division at the National Cancer Institute of Milan, Results and Conclusions: The sensitivity of gallium scan is very high (80-90%) in the staging and follow-up of Hodgkin's disease, and the method is also of great importance in the follow-up of lymphoma patients, We recommend scintigraphy to study the residual mediastinal mass after treatment. Our experiences during the follow-up of 189 lymphoma patients clearly showed the superior performance of gallium scan compared to MRI in the study of the mediastinal region after treatment. Sensitivity and specificity were both very high (90% and 96.9% vs 88.7% and 89.2%, respectively). Gallium scintigraphy can also be used to study the disease-free interval, post-treatment survival, early signs of recurrence and treatment response times. Comparison of the survival curves of 33 patients with diffuse large cell Non-Hodgkin's lymphoma examined at the National Cancer Institute showed a statistically significant difference (logrank test, P=0.0125) between patients with positive and those with negative gallium scan after 4-6 cycles of chemotherapy.
引用
收藏
页码:434 / 441
页数:8
相关论文
共 90 条
[1]   HIGH-DOSE GALLIUM IMAGING IN LYMPHOMA [J].
ANDERSON, KC ;
LEONARD, RCF ;
CANELLOS, GP ;
SKARIN, AT ;
KAPLAN, WD .
AMERICAN JOURNAL OF MEDICINE, 1983, 75 (02) :327-331
[2]  
ANGHILERI LJ, 1988, J NUCL MED, V29, P663
[3]   CHEMOTHERAPY FOR DIFFUSE LARGE-CELL LYMPHOMA - RAPIDLY RESPONDING PATIENTS HAVE MORE DURABLE REMISSIONS [J].
ARMITAGE, JO ;
WEISENBURGER, DD ;
HUTCHINS, M ;
MORAVEC, DF ;
DOWLING, M ;
SORENSEN, S ;
MAILLIARD, J ;
OKERBLOOM, J ;
JOHNSON, PS ;
HOWE, D ;
BASCOM, GK ;
CASEY, J ;
LINDER, J ;
PURTILO, DT .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) :160-164
[4]  
BARES R, 1996, ASSESSMENT HEMATOLOG, P67
[5]  
BONADONNA G, 1991, MANUALE ONCOLOGIA ME, P1011
[6]   ACCURACY OF RETROPERITONEAL ULTRASONOGRAPHY IN HODGKINS-DISEASE AND NON-HODGKINS LYMPHOMA [J].
BRASCHO, DJ ;
DURANT, JR ;
GREEN, LE .
RADIOLOGY, 1977, 125 (02) :485-487
[7]  
BRASCO DJ, 1977, CANCER, V39, P85
[8]   RESIDUAL MASS IN LYMPHOMA MAY NOT BE RESIDUAL DISEASE [J].
CANELLOS, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (06) :931-933
[9]  
CASTELLANI MR, 1992, 1 EUR S PED NUCL MED, P62
[10]  
CHITAMBAR CR, 1987, CANCER RES, V47, P3929